Objective. To describe a population of patients with symptomatic cryoglobulinaemia, comparing manifestations and outcome as a function of hepatitis C virus (HCV) status.
Cryoglobulins are plasma proteins that precipitate at low temperatures and dissolve at higher temperatures. They were first described in 1933 by Wintrobe and Buell w1x. In 1962, Lospaluto et al. w2x showed that cryoglobulins contain more than one immunoglobulin and that there may be rheumatoid factor activity within the cryoprecipitate. Brouet et al.'s w3x classification recognized three types of cryoglobulin: type I is composed of monoclonal immunoglobulins, usually IgM; type II consists of a combination of polyclonal and monoclonal immunoglobulins, with the latter having rheumatoid factor activity; type III is characterized by a combination of polyclonal immunoglobulins. Types II and III are termed mixed cryoglobulins.
Cryoglobulinaemia is an immune complex-mediated systemic vasculitis involving mostly small, but sometimes larger vessels, and can be associated with a variety of clinical conditions including myeloma, macroglobulinaemia, chronic infection and inflammatory disorders. Type I cryoglobulins can be found in patients with lymphoproliferative disorders, such as Waldenströ m's macroglobulinaemia or multiple myeloma, while mixed cryoglobulins are detected in patients with autoimmune disorders, lymphoproliferative disorders, or chronic infections. When no underlying disease is present, this is referred to as essential mixed cryoglobulinaemia (EMC).
In EMC, the possible role of hepatotropic viruses has been suggested by the high frequency of co-existing liver abnormalities w4x. Levo et al. w5x proposed hepatitis B virus (HBV) as a possible aetiology for EMC, but subsequent studies did not confirm the systematic responsibility or any relationship w6, 7x. Because liver involvement is frequent in EMC, the prevalence of anti-hepatitis C virus (HCV) antibodies and the correlation with clinical and serological parameters of EMC have been investigated w8-10x. A high prevalence of circulating anti-HCV antibodies and a very high HCV RNA concentration in the cryoprecipitate were found, thereby suggesting a close relationship between EMC and chronic HCV infection w8-10x.
The clinical manifestations of MC range from asymptomatic, mild vasculitis with palpable purpura, arthralgias and fatigue, to severe vasculitis with skin necrosis w11-13x, involvement of the kidneys w14-16x, peripheral nerves w17-20x, central nervous system (CNS) w21-25x, lungs w26x, myocardium w3, 27, 28x anduor gastrointestinal (GI) tract w29x. The aim of this study was to describe the clinical and biological manifestations observed in patients with symptomatic cryoglobulinaemia, in light of the discovery of HCV infection.
Patients and methods
Cryoglobulinaemia Venous blood was collected in a warm syringe and stored at 378C until it clotted. After centrifugation at 378C, the serum was collected and stored at 48C for 1 week. After isolation and washing, the cryoprecipitate was quantified. The components of the cryoprecipitate were detected using an automated immunonephelometric assay and characterized using immunofixation electrophoresis (Sebia, Issy-les-Moulineaux, France). In our experience, the cryoglobulin concentration did not exceed 80 mgul in 60 consecutive healthy blood donors. Therefore, only persistent cryoglobulin concentrations >80 mgul were considered for the diagnosis of cryoglobulinaemia. Only 33 sera could be tested for baseline cryoglobulin concentration, as described above. For the 16 other patients, cryoglobulins had been previously determined in other centres (and measured as a percentage of cryoprecipitate, i.e. cryocrit); by the time they were assessed in our centre, all patients had started therapy and thus, the cryoglobulin concentrations were probably lower than at baseline.
Patients
Cryoglobulins were detected in the sera of 179 patients seen between 1978 and 1998 in our Department of Internal Medicine. Cryoglobulins were sought in patients presenting with polyarthralgias or myalgias when vasculitis or systemic diseases were suspected, or systematically tested when HCV infection was present. Patients with transient cryoglobulins (n = 8), <80 mgul (n = 7), with HCV infection but no clinical manifestations (n = 61) or with a final diagnosis other than cryoglobulinaemia (n = 54) were not considered. The clinical characteristics of the 49 patients with clinical manifestations of cryoglobulinaemia are presented here.
HCV infection
Second-or third-generation HCV serological tests, ELISA-2, ELISA-3 (Ortho Diagnostic System, Raritan, NJ, USA) and RIBA-2 (ChironuOrtho Diagnostic System, Emeryville, CA, USA) were used. HCV RNA was detected using reverse transcriptasepolymerase chain reaction (RT-PCR). Blood samples were collected and RNA was extracted as previously described w30x.
Biochemical evaluation
Measurement of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, c-glutamyltransferase (cGT) and gammaglobulin levels, a test for rheumatoid factor, measurements of serum complement components (C3 and C4) and total haemolytic complement activity (CH50) were performed using standard procedures. Haematuria and proteinuria were also assessed for each patient. Patients with clinical manifestations consistent with vasculitis or connective tissue disease were systematically tested for antinuclear autoantibodies and antineutrophil cytoplasm antibodies.
Therapeutic modalities
Only patients with symptomatic cryoglobulinaemia were treated. HCV-infected patients were treated with subcutaneous interferon alpha (IFNa) at the dose of 3 MU thrice weekly for 6 or 12 months, with or without plasma exchange (PE) scheduled as follows: 60 mlukg bodyweight was removed and replaced with gelatin or human albumin three timesuweek for 2 weeks, two timesuweek for 2 weeks and one timeuweek for 3 weeks. No patients received ribavirin. PE was prescribed for glomerulonephritis with renal insufficiency, necrotic leg ulcers resistant to corticosteroids, recent-onset peripheral neuropathy, mononeuritis multiplex or CNS involvement. Corticosteriods (at the initial dose of 1 mgukguday, then tapered over several months) were given to patients presenting with severe visceral manifestations: glomerulonephritis with renal insufficiency, GI tract involvement, myocardial or CNS involvement or recent-onset mononeuropathy multiplex.
Treatment of HCV 2 patients and those for whom HCV was detected retrospectively several years after the onset of cryoglobulinaemia, consisted of corticosteroids with or without PE. Immunosuppressants (oral cyclophosphamide or azathioprine) were prescribed after relapse or failure of first-line therapy. IFNa (3 MU thrice weekly) was prescribed for patients refractory to immunosuppressants or when immunosuppressants were not tolerated or contraindicated.
Statistical analyses
Statistical analyses were performed using the x 2 test and appropriate corrections when necessary for categorical variables. Quantitative values, expressed as mean " standard deviation, were compared using Student's t-test. Actuarial survival curves were established using the Kaplan-Meier method.
Results

Cryoglobulin characteristics
Cryoglobulin concentrations were determined for 33 patients (mean concentration: 2.002 " 2.004 gul) and characterized in 43u49 patients ( 
Patient characteristics
Our patient population consisted of 31 women and 18 men, with a mean age at diagnosis of 59.96 " 12 yr (femaleumale ratio = 1.72).
Presenting symptoms
In this retrospective study, 34 patients had at least one cryoglobulinaemia-defining manifestation at first presentation. Palpable purpura (55.9%) was the most frequent presenting symptom, followed by arthralgias (29.4%), peripheral neuropathy (20.6%) anduor myalgias (8.8%), with renal disease (5.9%) and leg ulcers (5.9%) rarely present at onset.
Clinical manifestations from onset to the end of follow-up (Table 2) Cutaneous and vasomotor symptoms. Forty (81.6%) patients had skin involvement. Palpable purpura was the most common manifestation, usually beginning in the legs. Skin biopsies of purpuric lesions confirmed the diagnosis of vasculitis in 22u27 patients (81.5%). Leg ulcers developed in 20 patients (40.8%). Raynaud's phenomenon was noted in 17 (34.7%), livedo in three (6.1%), urticaria in two (4.1%) and subcutaneous nodules in one (2%).
Rheumatological manifestations. Arthralgias were present in 25 patients (51%) and diffuse myalgias were present in 10 (20.4%).
Neurological disorders. Peripheral neuropathy was present in 27 patients (55.1%) and was documented by electromyography in 25 patients: 14 symmetrical distal sensory polyneuropathies and 11 mononeuritis multiplex. Nerve biopsies from 15 patients showed lymphocytic vasculitis involving epineurial small vessels in 14 patients (93.3%) and was normal in one patient. CNS involvement was suspected in three patients: one had vertigo; another cerebral ischaemia with multifocal infarcts on magnetic resonance imaging; the third patient had dysarthria, aphasia and confusion which regressed dramatically after intensive PE.
Renal disease. Renal manifestations were present in 12 patients (24.5%). Renal insufficiency, defined as creatininaemia >140 mmolul, was present in five patients, microscopic haematuria was found in 9u12 patients. Proteinuria (>1 guday) was present in 10u12 patients (83%), seven (58%) of whom had nephrotic syndrome. Renal biopsies performed in 10 patients revealed membranous proliferative glomerulonephritis in all of them; vasculitis was seen in two patients. Six of these 12 patients had type II IgM kappa, three had type III, and for three, cryoglobulins were not typed. Eight patients were HCV + and four were HCV 2 . GI involvement. Episodes of diffuse abdominal pain, one of them with GI bleeding, were observed in six patients (12.2%). None necessitated laparotomy. Coeliomesenteric angiography, performed in two patients, did not show microaneurysms; distal opacification was slow and late, consistent with diffuse distal mesenteric ischaemia.
Cardiac manifestations. During the course of the disease, four patients (8.2%) (mean age 63.3 yr) had myocardial infarctions; only one of them had a risk factor for coronary disease (hypertension). Mitral insufficiency was diagnosed in one patient and pericarditis in another.
Respiratory tract diseases. Pleural effusions were observed in two patients: one had a nephrotic syndrome and the other suffered from pulmonary fibrosis associated with progressive systemic sclerosis.
Sicca syndrome. Sicca syndrome, defined as dryness of the mouth anduor the eyes, was found in 17 patients (34.7%), but none of them had anti-SSA antibodies. Four salivary gland biopsies could be reviewed and showed diffuse, non-nodular, lymphocytic infiltrates, without ductal atrophy; vasculitis was seen in one patient.
Miscellaneous. Asthenia, weight loss anduor fever were observed in 18 patients (36.7%). Mild depression was noted in six patients (12.2%), two during the first Only arthralgias were significantly more frequent in HCV + patients (P = 0.025).
3 months of IFNa therapy, while the other four did not receive IFNa. Two men had orchitis (11.1%). Vasculitis was found in two unusual biopsy sites: a liver biopsy in the first, and a collateral arteriole of the temporal artery biopsy in the second. Anti-thyroid autoantibodies were negative in all 16 patients tested; dysthyroidism was not found in any of them.
Associated diseases (Table 3) Infectious diseases. Anti-HCV antibodies were present in 33 (67.3%) patients (23 women, 10 men), absent in 14 and not tested in two. HCV RNA was sought in 25 HCV + patients and was present in all cases.
One HCV + patient was co-infected with human immunodeficiency virus (HIV). Serum hepatitis B surface antigen was detected in two patients, one of whom was co-infected with HCV and the other was positive for anti-hepatitis Be antibodies and negative for HBV DNA.
Haematological diseases. Two patients (two men, mean age 54 yr) had monoclonal gammopathies (one IgG kappa and one IgM kappa) of unknown significance.
Systemic diseases. Twenty patients (15 women, five men, mean age 59.3 " 10.8 yr) had systemic disease as detailed in Table 3 . The femaleumale sex ratio was 3. Seventeen had sicca syndrome (10 with HCV infection), one had progressive systemic sclerosis (and HCV infection), one had primary biliary cirrhosis and one had co-existing polyarteritis nodosa (HCV and HBV co-infection).
Only six patients (three women, three men; mean age 71.4 " 15.3 yr) had no associated or underlying disease.
Laboratory findings (Table 4 ) Rheumatoid factor was sought in 34u49 patients and detected in 16 (47.1%). Low C4 levels were noted in 36u43 (83.7%) patients and CH50 was low in 14u25 (56%) patients. Elevated serum ALT was observed in 21u49 (42.8%) patients, elevated serum AST was observed in 19u49 (38.8%) patients. Transaminases were significantly higher in the HCV + patients than in the HCV 2 patients (57.6 vs 14.3%, P < 0.05). Polyclonal hypergammaglobulinaemia was found in 10u49 (20.4%), hypogammaglobulinaemia was found in 12u49 (24.5%).
Histological findings (Table 5 ) One hundred biopsies from 39 patients were reviewed, and an attempt was made to classify the vasculitic lesions according to vessel diameter (Table 5) . Venules, capillaries and arterioles were considered to be small vessels; arteries with a diameter >200 mm were considered to be medium sized.
Forty-nine biopsies (49%) showed evidence of vasculitis: 43 (87.8%) involved small vessels, six (12.2%) involved medium-sized vessels, five of them co-existing with small vessel vasculitis. In seven biopsies, the inflammatory infiltrate was perivascular and did not invade the vessel wall.
Vascular infiltrates were composed as follows: predominantly neutrophils (15.2%), predominantly mononuclear cells (45.4%), association of the two (39.4%). Immunofluorescence assays for immunoglobulins and C3 deposits were negative for 22%, and slightly positive for C3 and IgM in 78%. Proof of vasculitis was most often obtained in skin (primarily palpable purpura: 81.5%), neuromuscular (especially epineurial vessels: 14u15 or 93.3%), and muscle (5u10 or 50%) biopsies.
Patients with HCV infection (Table 2 ) Thirty-three patients (67.3%) had HCV infection. Their mean age was 58.8 " 10.3 yr vs 61.5 " 14 yr for the HCV 2 patients (NS). The femaleumale sex ratio was 0.43. The route of contamination was known for 14: intravenous drug use (n = 3) or blood transfusion (n = 11). The mean time between contamination and diagnosis of cryoglobulinaemia was 13.8 " 8 yr. Biochemical data are reported in Table 4 . No significant difference was found between the mean cryoglobulin concentrations of the HCV + patients (1.911 " 1.628 gul) and those of the HCV 2 patients (2.230 " 2.865 gul). AST and ALT were significantly higher in the HCV + patients (P = 0.05; see Table 4 ). Only arthralgias were significantly more frequent in HCV + patients (P = 0.025; see Table 2 ).
Treatment and outcome
Therapeutic modalities. First-line therapy for HCVinfected patients consisted of IFNa (23 patients), with corticosteroids (22 patients) or PE (11 patients), according to the severity of the clinical manifestations. Immunosuppressants (cyclophosphamide for four patients and azathioprine for one patient) were prescribed after failure of first-line therapy.
During IFNa therapy, cutaneous manifestations of the HCV + patients regressed, but recurred when IFNa was stopped. Sensory peripheral neuropathy stabilized but did not regress, even when IFNa was combined with corticosteroids anduor PE. Nevertheless, no exacerbation of peripheral neuropathy was seen. Prolonged virus eradication could not be obtained in any of the patients.
First-line therapy for HCV 2 patients and patients for whom HCV was detected retrospectively and sometimes several years after the onset of the disease, consisted of corticosteroids (11 patients) with or without PE (five patients). Immunosuppressants (cyclophosphamide for five patients) or IFNa (three patients) were prescribed after relapse or failure of first-line therapy.
Twenty-nine patients received more than one treatment regiment during the course of the disease. Two patients (one HCV + and one HCV 2 ) did not receive any treatment because the flare was mild and regressed spontaneously.
Eighteen patients (13 HCV + , five HCV 2 ) underwent PE, with (n = 12) or without (n = 6) low-dose corticosteroids and with (n = 11) or without (n = 7) IFNa. Most of them had recent-onset peripheral neuropathy or recurrent leg ulcers. All of them had dramatic regression of ulcers, while peripheral neuropathy responded poorly. Four patients with recurrent and painful leg ulcers were successfully treated with PE over several years. Pertinently, comparison of the long-term survival rates between patients who were treated with PE and those who were not showed a slight but significant difference in favour of those without PE (Fig. 1A) . The explanation is probably complex and is discussed below.
Outcome. For 25u35 (71.4%) patients, clinical remission could be obtained but clinical manifestations recurred in all of them when treatment was stopped, and maintenance therapy with IFNa, low-dose corticosteroids anduor PE was necessary. For 14 patients, the long-term response to therapy was not well documented or was unknown.
Eight (16.3%) patients (six HCV + , two HCV 2 ) died during follow-up, and the 5-yr survival curves did not differ significantly as a function of HCV status (Fig. 1B) or cyclophosphamide administration (Fig. 1C) . The mean age at the time of death was 66.2 yr, and the mean time between diagnosis and death was 38.7 " 36.7 months. The causes of death were: systemic infection in two (both with septic shock on indwelling catheters while receiving long-term corticosteroids, in addition to PE for one), major clinical deterioration in two patients (the first was being treated with long-term corticosteroids and had previously received cyclophosphamide; the second was treated with corticosteroids and IFNa and had been undergoing intensive PE for 2 weeks), stroke complicated by aspiration pneumonia in two patients (the first was on low-dose corticosteroids and PE for chronic and painful leg ulcers, the second received corticosteroids and IFNa), GI bleeding in one (untreated HCV-related cirrhosis, 2 yr after the transient efficacy of IFNa alone against purpura and peripheral neuropathy) and HCV-related hepatocarcinoma in a patient on corticosteroids 2 months after the end of PE which had successfully treated mononeuritis multiplex.
Discussion
Clinical manifestations Cryoglobulinaemia, a systemic vasculitis involving primarily small vessels, can be associated with lymphoproliferative malignancies, autoimmune diseases, or chronic bacterial, fungal or viral infections w3, 28x, whereas transient and asymptomatic cryoglobulins can be detected during acute infectious diseases and even in healthy blood donors w31x. Since the discovery of HCV, this virus has been considered to be the cause of cases formerly diagnosed as EMC w8-10, 31, 32x. When cryoglobulins are systematically tested, mixed cryoglobulins are found in more than half of HCV + patients; but in the large majority of them, they remain at low concentrations and are clinically asymptomatic w31, 33x. The long-term significance of asymptomatic cryoglobulinaemia in HCV + patients remains to be elucidated.
The present study set out to describe the characteristics, aetiology and outcome of patients with cryoglobulinaemia observed in a single department of internal medicine.
Clinical and biological manifestations of cryoglobulinaemia were described before the discovery of HCV w3, 28, 34x (see Table 6 ). The frequency of cutaneous manifestations in our patients was comparable with those reported in the literature, and no difference was observed with regard to HCV infection w3, 11-13, 28x.
It is pertinent that four of our patients had long histories of recurrent and painful chronic leg ulcers requiring numerous hospitalizations; their general conditions progressively deteriorated over several years, leading to death, even though three of them never developed extracutaneous involvement. These deaths might have resulted from the cumulative toxicity of long-term low-dose corticosteroids. In our experience, chronic leg ulcers never healed with IFNa alone; repeated PE was the sole effective therapy.
Peripheral neuropathy was more frequent in our patients (55.1%) than previously published frequencies, which vary from 8.3 to 53% w3, 18-20, 28, 31, 35x. Our patients presented with two distinct forms of neurological involvement: progressive and chronic distal sensory polyneuropathy involving the legs, or acute mononeuritis multiplex. Epineurial vasculitis was found in 14u15 nerve biopsies.
One of our three patients with CNS manifestations recovered dramatically from encephalopathy after intravenous administration of corticosteroids and one PE. We postulate that encephalopathy could have been the consequence of a rapid rise in the cryoglobulin concentration, as it was >15 gul. Reversible acute or subacute encephalopathy has been described w21x. In another patient, magnetic resonance imaging revealed multifocal T2-weighted hypersignals. Stroke-like syndromes have been attributed to ischaemia or haemorrhage w22, 23, 25x. In our experience, the frequency of renal involvement (24.5%) was comparable with that observed in other series w3, 28x; only one patient required chronic dialysis. In the Italian experience w16x, renal insufficiency usually occurred late in the course of the disease in <10% of the patients. Myocardial involvement is rare. In our study, four patients (mean age 63.3 yr) suffered myocardial infarctions, three of them did not have any coronary risk factor; one underwent a coronarography that showed occlusion of the right coronary artery. Gorevic et al. w28x reported that 12 patients required management for congestive heart failure, two for pericarditis and four for myocardial infarctions; among the nine postmortem examinations, coronary vasculitis was found in two patients, and a subendothelial infarct was found in one.
As observed in our patients, GI involvement is common (<20%) and is thought to be due to intestinal vasculitis.
In contrast to HBV-related polyarteritis nodosa w36x, only two of our HCV + patients had orchitis, neither was co-infected with HBV. All of our patients experienced more than one flare; only purpuric rashes regressed spontaneously within a few weeks, while painful leg ulcers necessitated continuing care or intensive and prolonged therapies, such as PE.
Comparison of HCV
+ and HCV 2 patients
Few studies have compared HCV + and HCV 2 cryoglobulinaemic patients. In our experience, the mean age and sex ratio of HCV + and HCV 2 patients did not differ significantly. Unlike Cacoub et al. w31x, we did not find higher cryoglobulin concentrations in our HCV + patients (see Table 4 ). In two French series w31, 35x of 105 and 63 patients, hepatic and cutaneous involvement were more frequent, and cryoglobulin levels higher in HCV + patients. Buezo et al. w37x also found a high frequency of skin manifestations in HCV + patients. In our study, only arthralgias (P < 0.02) and elevated serum transaminase levels (P < 0.05) were significantly more frequent in HCV + patients. These findings are not surprising as these patients had chronic HCV infections. Others have suggested a role for HCV in leucocytoclastic vasculitis independently of cryoglobulins and liver involvement w38, 39x. The direct role of HCV, suggested by Agnello and Abel w40x, who detected HCV RNA in biopsy specimens from six patients with cutaneous vasculitis, was not confirmed by other authors w41x.
Peripheral neuropathy was present in more than half of our patients, regardless of HCV status. It was recently reported that HCV RNA was detected in nerve biopsies from five HCV + patients. Using in situ Rt-PCR, HCV RNA was localized in the epineurium, suggesting a major role for HCV in patients with neuropathies and HCV-related mixed cryoglobulinaemia (MC) w42x. But Khella et al. w43x suggested indirect damage of the nerves by cryoglobulins or inflammatory cells because they did not find HCV particles in their study on nerve biopsies.
No difference was found for renal involvement in terms of histological findings and mean creatininaemia between our HCV + and HCV 2 patients. Although some authors reported promising results with PE, indications of PE in MC remain controversial w45-48, 57, 58x. As already published, prompt regression of skin and joint manifestations was obtained, whereas neurological improvement was slower w45x. The beneficial effect was observed after the first 2-3 weeks of treatment. Other authors also found PE to be effective against recurrent or refractory leg ulcers w56x, and was performed every 10-14 days in some patients as a maintainance therapy w60x. The high mortality rate of our patients who had been treated with PE cannot be explained by a single factor: these patients had long histories of recurrent disease and all had received prolonged corticosteroids with or without immunosuppressants. The causes of death were different, but two deaths resulted from iatrogenic infectious complications on indwelling catheters, whereas another followed the progressive deterioration of the patient's general condition, even though no specific involvement of the heart, CNS, lungs or acute renal failure was present. In our opinion, patients with recurrent, chronic and painful leg ulcers undergo slow general deterioration and are at high risk of infectious complications.
In our study, eight (16.3%) patients died. Most of them had a long history of cryoglobulinaemia with corticosteroids anduor immunosuppressive therapy. Only one of them (who was <50 yr old) developed renal involvement, but it was not the cause of death. The others were over 60 yr old, without renal involvement. It should be noted that, although heart disease was not the leading cause of death, three of our four patients with myocardial infarction died during therapy with prolonged PE and oral corticosteroids. Specific myocardial involvement may be underdiagnosed, as it is not a rare finding on autopsy w28, 34x and could be a poor prognostic factor for patients with cryoglobulinaemia, especially when prolonged immunosuppressive therapy is still needed. Some authors found that renal disease was associated with a poor prognosis w28, 34x, whereas Cordonnier et al. w61x reported that death was caused by extrarenal complications, e.g. infections, cardiovascular disease, CNS involvement or haematological malignancies. Tarantino et al. w62x reported the outcomes of 105 patients with EMC and renal disease: 42 died of cardiovascular disease, liver disease or infection; 15 developed chronic renal failure; two achieved complete remission; 15 experienced regression of only renal manifestations; 31 were alive with recurrent or persistent manifestations. Independent risk factors for death or dialysis were age >50 yr, purpura, splenomegaly, cryocrit = 10%, plasma C3 level <54 mgudl and serum creatinine >140 mmolul.
None of our patients has developed lymphoma; one HCV + patient infection had isolated lymphoid infiltrates on a bone marrow biopsy, but the search for clonality was negative. This absence of lymphoma is strikingly different from the Italian and North American experiences w63-67x; in those studies, the risk of developing lymphoma rose from 13% at the time of MC diagnosis in a prospective study w67x to 35% after 10 yr of follow-up w63x. This discrepancy has not been correlated to HCV genotypes and remains unexplained.
In this retrospective study, the role of the different regimens is difficult to assess as some patients received immunosuppressive therapy before the discovery of HCV. Furthermore, our department is a tertiary care centre, and many patients had received various treatments, including corticosteroids or immunosuppressants. It is known that long-term eradication of HCV with IFNa is more difficult to obtain when the duration of HCV infection is longer and the HCV load is higher, as it is in immunocompromised patients w68x.
Whether prolonged exposure to immunosuppressants can influence the course of HCV-related MC remains unknown. In our experience, short-term control of vasculitic manifestations was obtained with corticosteroids, but most patients relapsed when therapy was tapered or stopped.
In light of the central role of HCV, it seems logical to state that therapeutic strategies for HCV-related MC must include HCV eradication. In a controlled study on patients with HCV-related MC, the disappearance of HCV RNA from serum during IFNa therapy correlated with clinical and biological improvement, but was not predictive of prolonged virological and clinical remissions w53x. Preliminary results with ribavirin alone w69x or combined with IFNa w58, 70x are encouraging. In a French study w69x, five patients who did not tolerate IFNa were treated with ribavirin alone for 10-36 months; they all benefited from significant clinical improvement but no virological response was obtained. Large-scale trials are needed to confirm those preliminary data.
